Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5250 Target Snapshot

Tyrosine-protein kinase JAK3 · SINGLE PROTEIN · Mus musculus

22Compounds
19Assays
2Approved Drugs
28.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q62137. Use UniProt Q62137 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q62137 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase JAK3 as ChEMBL target CHEMBL5250, mapped to UniProt Q62137. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase JAK3
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
ChEMBL target ID
CHEMBL5250
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q62137
Tyrosine-protein kinase JAK3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase JAK3 is the right protein anchor across sources, using UniProt Q62137 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase JAK3
UniProt AccessionQ62137
Component TypeProtein
Sequence Length1100 aa

Tyrosine-protein kinase JAK3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase JAK3, mapped to UniProt Q62137. Sequence length is 1100 aa.

Mapped IDQ62137
Review nameTyrosine-protein kinase JAK3
OrganismMus musculus
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5028.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL221959 7.32 IC50 48.0 Approved
CHEMBL3039513 7.3 IC50 50.0 Clinical
CHEMBL4776512 6.25 IC50 563.7 Preclinical
CHEMBL4564280 6.12 IC50 764.0 Preclinical
CHEMBL4746272 6.11 IC50 770.0 Preclinical
CHEMBL3940537 6.07 IC50 848.0 Preclinical
CHEMBL1650951 5.89 IC50 1294.0 Preclinical
CHEMBL4750184 5.8 IC50 1600.0 Preclinical
CHEMBL3966342 5.76 IC50 1724.0 Preclinical
CHEMBL3622821 5.73 IC50 1860.0 Approved
Distribution

pChEMBL Value Distribution

6
5.0
8
5.5
7
6.0
2
6.5
2
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOFACITINIB
CHEMBL221959
Approved 2012
Assay Landscape

Assay Landscape

19
Total Assays
14
Tested Compounds
2
Assay Types
Binding — 17 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 11 14 5.9
tissue-based format 4 0
single protein format 2 0
ADME — 2 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 3 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine